Jasper Therapeutics (JSPR) said Wednesday that preliminary data from an ongoing phase 1b/2a study of subcutaneously administered briquilimab as a treatment for chronic spontaneous urticaria showed "substantial reductions" in disease activity.
The company said the 49-patient study showed clinical responses as early as one week after the first dose as well as "durable" clinical responses across multiple doses.
Chronic spontaneous urticaria is a condition which causes hives to appear.
Jasper Therapeutics' shares were down 44% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.